BETHLEHEM, Pa., April 15, 2016 -- OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that Michael Reed, Ph.D. has been named as the Company’s Senior Vice President of Research and Development and Chief Science Officer. He will begin working at the Company on April 18, 2016.
Dr. Reed brings to OraSure Technologies more than 20 years of experience in life sciences and diagnostics research and development across an extensive array of disciplines including globally regulated IVD development and commercialization of molecular and cellular applications and systems. He joins OraSure after having spent the last eight years as part of the management team at Beckman Coulter, a global diagnostics and life sciences company within the Danaher Corporation.
At Beckman Coulter, Dr. Reed served in a variety of leadership positions including Director of Global Assay and Applications Development for the Beckman Coulter Life Science business encompassing flow cytometry, genomics and capillary electrophoresis reagent development and Director of Scientific Affairs for the Cellular Analysis Business Group, including flow cytometry and hematology reagent research and development, and clinical affairs. Under his leadership, the Company launched and commercialized over 300 products globally across multiple disciplines.
Prior to his work at Beckman Coulter, Dr. Reed served as Director of Product Development with Osmetech Molecular Diagnostics where he led the effort to develop two U.S. FDA 510K cleared IVD systems for cystic fibrosis genotyping and a pharmacogenetics test to guide warfarin dosing. He also worked at the predecessor company – Clinical Micro Sensors.
“Mike will be a valuable addition to our senior management team and we will benefit from his global leadership in research and development and specifically his expertise in regulated assay development, genomics and molecular diagnostics,” stated Douglas A. Michels, President and CEO of OraSure Technologies.
Dr. Reed received a Ph.D. degree in Biochemistry from the University of Adelaide (Australia) and a BSc. in Biochemistry from The Australian National University (Canberra, Australia). He conducted post-doctoral research at the Beckman Research Institute at the City of Hope in Duarte, California.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health.
For more information on OraSure Technologies, please visit www.orasure.com.
Investor Contact: Ronald H. Spair Chief Financial Officer (610) 882-1820 [email protected] Media Contact: Ron Ticho SVP, Corporate Communications (484) 353-1575 [email protected]


Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Instagram Outage Disrupts Thousands of U.S. Users
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 



